Abstract
Lithium salts (Li) are used to treat bipolar disorder patients. Li inhibits inositol-monophosphatase (IMPase)-1. Calbindin D28k (calbindin) and S100B enhance IMPase-1 activity. We compared our in silico model of the IMPase-1/calbindin complex with the crystal structure of S100B. Although calbindin and S100B have a low sequence homology, they seem to activate IMPase-1 in a similar mode. It is reasonable that molecules interfering with the interaction of IMPase-1 with either of its activators will have Li-like effects.
| Original language | English |
|---|---|
| Pages (from-to) | 2042-2044 |
| Number of pages | 3 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 58 |
| Issue number | 4 |
| DOIs | |
| State | Published - 26 Feb 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
Fingerprint
Dive into the research topics of 'Calbindin D28k and S100B have a similar interaction site with the lithium-inhibitable enzyme inositol monophosphatase-1: A new drug target site'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver